According to Dr. Liechti, “LSD and psilocybin are increasingly used in neuroscience and in psychiatry as pharmacological tools to induce and investigate alterations in waking consciousness and associated brain functions and also as potential medications. However, there are no modern studies comparing these two substances directly within the same clinical study and research subjects and using validated psychometric tools. We are aiming to compare the acute effects of the two substances including different doses and placebos to see whether there are differences in the alterations in mind produced by them.”
MindMed entered an exclusive license agreement with the University Hospital Basel. Under the deal, the company will retain an exclusive license to all IP and any patents generated from data or findings in the study and related work on psilocybin.
—————————————-
Have a story you want USA Herald to cover? Submit a tip here and if we think it’s newsworthy, we’ll follow up on it.
